To include your compound in the COVID-19 Resource Center, submit it here.

ODAC recommends Campath

An FDA advisory committee on Thursday voted 14-1 to recommend accelerated approval of Campath alemtuzumab, a monoclonal antibody developed by Millennium (MLNM) and

Read the full 235 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE